HOMA-IR: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease.
Adult
Age Factors
Biomarkers
/ blood
Blood Glucose
/ analysis
Cross-Sectional Studies
Disease Progression
Dyslipidemias
/ blood
Female
Humans
Insulin
/ blood
Insulin Resistance
Japan
Lipids
/ blood
Liver Cirrhosis
/ blood
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
/ blood
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
NAFLD
hepatic fibrosis
insulin resistance
type 2 diabetes mellitus
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
03
10
2018
revised:
06
12
2018
accepted:
20
12
2018
pubmed:
3
1
2019
medline:
11
2
2020
entrez:
3
1
2019
Statut:
ppublish
Résumé
Although non-alcoholic fatty liver disease (NAFLD) is common in the general population, identifying patients with advanced fibrosis remains a challenge. We investigated whether the homeostasis model assessment parameter of insulin resistance (HOMA-IR), an index of IR and one of the most important metabolic factors, is an independent predictive factor for advanced fibrosis in nondiabetic patients with NAFLD. This was a retrospective, cross-sectional multicenter study. We included 361 patients with biopsy-proven NAFLD who had not been diagnosed with type 2 diabetes mellitus: 175 (48%) were women and 48 (13%) had advanced fibrosis. We used simple random sampling; the sampling ratio of the estimation and validation groups was 7:3. A logistic model was constructed for both the estimation and validation groups. The explanatory variables were age ≥ 49 years, sex (women), body mass index ≥ 26.7 kg/m In the estimation group, univariate and multivariate analyses showed that age, dyslipidemia, and HOMA-IR were independent predictors of advanced fibrosis. In the validation group, only age and HOMA-IR were found to be independent predictors of advanced fibrosis. Homeostasis model assessment parameter of insulin resistance was an independent predictor of advanced liver fibrosis in nondiabetic patients with NAFLD. Given that most patients with NAFLD are nondiabetic, it is important to set goals with respect to improving IR to subsequently reduce liver fibrosis.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Although non-alcoholic fatty liver disease (NAFLD) is common in the general population, identifying patients with advanced fibrosis remains a challenge. We investigated whether the homeostasis model assessment parameter of insulin resistance (HOMA-IR), an index of IR and one of the most important metabolic factors, is an independent predictive factor for advanced fibrosis in nondiabetic patients with NAFLD.
METHODS
METHODS
This was a retrospective, cross-sectional multicenter study. We included 361 patients with biopsy-proven NAFLD who had not been diagnosed with type 2 diabetes mellitus: 175 (48%) were women and 48 (13%) had advanced fibrosis. We used simple random sampling; the sampling ratio of the estimation and validation groups was 7:3. A logistic model was constructed for both the estimation and validation groups. The explanatory variables were age ≥ 49 years, sex (women), body mass index ≥ 26.7 kg/m
RESULTS
RESULTS
In the estimation group, univariate and multivariate analyses showed that age, dyslipidemia, and HOMA-IR were independent predictors of advanced fibrosis. In the validation group, only age and HOMA-IR were found to be independent predictors of advanced fibrosis.
CONCLUSIONS
CONCLUSIONS
Homeostasis model assessment parameter of insulin resistance was an independent predictor of advanced liver fibrosis in nondiabetic patients with NAFLD. Given that most patients with NAFLD are nondiabetic, it is important to set goals with respect to improving IR to subsequently reduce liver fibrosis.
Substances chimiques
Biomarkers
0
Blood Glucose
0
Insulin
0
Lipids
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1390-1395Subventions
Organisme : Japan Society for the Promotion of Science
ID : 17K09437
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N. Engl. J. Med. 2017; 377: 2063-2072.
Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort. Hepatology 2016; 64: 1969-1977.
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J. Hepatol. 2017; 67: 862-873.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.
Angulo P, Kleiner DE, Dam-Larsen S et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389-97.e10.
Ekstedt M, Hagström H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-1554.
Hagstrom H, Nasr P, Ekstedt M et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 2017; 67: 1265-1273.
Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J. Hepatol. 2018; 68: 305-315.
Hossain N, Afendy A, Stepanova M et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009; 7: 1224-1229 1229: e1-2.
Nakahara T, Hyogo H, Yoneda M et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J. Gastroenterol. 2014; 49: 1477-1484.
Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol. 2007; 22: 1086-1091.
Garcia-Monzon C, Lo Iacono O, Mayoral R et al. Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J. Hepatol. 2011; 54: 142-152.
Bugianesi E, Marchesini G, Gentilcore E et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006; 44: 1648-1655.
Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. Am. J. Gastroenterol. 2010; 105: 336-344.
World Medical Association I. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J. Indian Med. Assoc. 2009; 107: 403-405.
American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29: S43-S48.
Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1195.
Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.
Hirata T, Higashiyama A, Kubota Y et al. HOMA-IR values are associated with glycemic control in Japanese subjects without diabetes or obesity: the KOBE study. J. Epidemiol. 2015; 25: 407-414.
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 330-344.
Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013; 10: 686-690.
Reaven GM. The metabolic syndrome: time to get off the merry-go-round? J. Intern. Med. 2011; 269: 127-136.
Petersen KF, Dufour S, Feng J et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 18273-18277.
Lee JW, Brancati FL, Yeh HC. Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997-2008. Diabetes Care 2011; 34: 353-357.
Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J. Gastroenterol. 2017; 52: 164-174.
Park JH, Cho B, Kwon H et al. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int. 2015; 35: 2537-2546.
Ota T, Takamura T, Kurita S et al. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 2007; 132: 282-293.
Svegliati-Baroni G, Ridolfi F, Di Sario A et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743-1751.
Amer J, Salhab A, Noureddin M et al. Insulin signaling as a potential natural killer cell checkpoint in fatty liver disease. Hepatol. Commun. 2018; 2: 285-298.
Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced Liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern. Med. 2017; 177: 633-640.
Masuda K, Noguchi S, Ono M et al. High fasting insulin concentrations may be a pivotal predictor for the severity of hepatic fibrosis beyond the glycemic status in non-alcoholic fatty liver disease patients before development of diabetes mellitus. Hepatol. Res. 2017; 47: 983-990.
Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut 2009; 58: 1566-1567 author reply 7.
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011; 34: 274-285.
Patel YA, Imperial JC, Muir AJ et al. Baseline parameters in clinical trials for nonalcoholic steatohepatitis: recommendations from the liver forum. Gastroenterology 2017; 153: 621-625 e7.
Alkhouri N, Poordad F, Lawitz E. Management of nonalcoholic fatty liver disease: lessons learned from type 2 diabetes. Hepatol. Commun. 2018; 2: 778-785.